Clinical tests of the novel small-molecule inhibitor of p38α MAPK, VX-702, have resulted in an all-too-familiar outcome: modest clinical efficacy and transient inhibition of inflammatory markers.

(A) PFS and (B) OS in class 2 versus other MAP2K1 mutant tumors in the whole MAPK targeted therapy-treated cohort. (C) PFS and (D) OS in class 2 versus other MAP2K1 mutant tumors in patients treated ...

Sorafenib is an oral tyrosine kinase inhibitor able to inhibit VEGF receptors 1, 2 and 3, PDGF receptors α and β, RET, Flt3, c-KIT and the RAF kinase and MAPK pathways. Over 10,000 patients have ...

Erasca is a biotech company focused on developing therapies for RAS/MAPK pathway-driven cancers with a strong financial ...

"With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further ...

inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published in JACC ...

and CRAF potentially creating a more complete and durable anti-tumor response through maximal RAS/MAPK pathway inhibition. In contrast to currently available MEK-only inhibitors, avutometinib ...

inhibitor, reduces mortality and morbidity in children with severe hypertrophic cardiomyopathy (HCM) caused by pathogenic variants in the RAS/MAPK pathway, according to a study published today in ...

“With the addition of VS-7375, a potential best-in-class oral KRAS G12D (ON/OFF) inhibitor, we are well-positioned to further establish our leadership in targeting RAS/MAPK pathway-driven ...